Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma

References

• Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020 Sep24;383(13):1218–1230.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Bladder cancer (version 6.2021 [cited 2021 Dec 6]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
   Google Scholar
• Swami U, Grivas P, Pal SK, et al. Utilization of systemic therapy for treatment of advanced urothelial carcinoma: lessons from real world experience. Cancer Treat Res Commun. 2021;27:100325.
   PubMedGoogle Scholar
• US Food and Drug Administration. FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer 2021. [ cited 2021 Oct 24]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sacituzumab-govitecan-advanced-urothelial-cancer
   Google Scholar
• Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021 Aug 1;39(22):2474–2485.
   PubMed Web of Science ®Google Scholar
• Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016 Jun;17(6):e254–e262.
   PubMed Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315–337.
   PubMed Web of Science ®Google Scholar
• Damelin M, Zhong W, Myers J, et al. Evolving strategies for target selection for antibody-drug conjugates. Pharm Res. 2015 Nov;32(11):3494–3507.
   PubMed Web of Science ®Google Scholar
• Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs. 2011 Jan;20(1):75–85.
   PubMed Web of Science ®Google Scholar
• Wang J, Day R, Dong Y, et al. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther. 2008 Feb;7(2):280–285.
   PubMed Web of Science ®Google Scholar
• Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015 Mar;6(3–4):84–105.
   PubMedGoogle Scholar
• Bignotti E, Todeschini P, Calza S, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010 Mar;46(5):944–953.
   PubMed Web of Science ®Google Scholar
• Fong D, Moser P, Krammel C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008 Oct 21;99(8):1290–1295.
   PubMed Web of Science ®Google Scholar
• Leung K. (89)Zr-Desferrioxamine-anti-epithelial glycoprotein-1 hRS7 humanized monoclonal antibody. Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD) 2004.
   Google Scholar
• Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019 Aug/Sep;11(6):987–995.
   PubMed Web of Science ®Google Scholar
• Gokduman K. Strategies targeting DNA topoisomerase I in cancer chemotherapy: camptothecins, nanocarriers for camptothecins, organic non-camptothecin compounds and metal complexes. Curr Drug Targets. 2016;17(16):1928–1939.
   PubMed Web of Science ®Google Scholar
• Schreiber AR, Andress M, Diamond JR. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. Expert Rev Anticancer Ther. 2021 Oct;22:1–9.
   PubMedGoogle Scholar
• Iyer G, Rosenberg JE. Novel therapies in urothelial carcinoma: a biomarker-driven approach. Ann Oncol. 2018 Dec 1;29(12):2302–2312.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, McBride WJ, Cardillo TM, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (Sacituzumab Govitecan). Clin Cancer Res. 2015 Nov 15;21(22):5131–5138.
   PubMed Web of Science ®Google Scholar
• Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019 Feb 21;380(8):741–751.
   PubMed Web of Science ®Google Scholar
• Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel Anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015 Sep 1;21(17):3870–3878.
   PubMed Web of Science ®Google Scholar
• Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017 Oct 1;123(19):3843–3854.
   PubMed Web of Science ®Google Scholar
• Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev. 2008 Nov;34(7):656–669.
   PubMed Web of Science ®Google Scholar
• Faltas B, Goldenberg DM, Ocean AJ, et al. Sacituzumab govitecan, a novel antibody–drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer. 2016 Feb;14(1):e75–9.
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Faltas BM, Lam ET, et al. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): results from a phase I/II study. J Clin Oncol. 2019;37(7_suppl): 354–354.
   Web of Science ®Google Scholar
• Petrylak DP, Tagawa ST, Jain RK, et al. Early results of TROPHY-U-01 Cohort 2: sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy. J clin oncol. 2020;38(15_suppl):5027.
   Web of Science ®Google Scholar
• Grivas P, Tagawa ST, Bellmunt J, et al. TROPiCS-04: study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy. J clin oncol. 2021;39(6_suppl): TPS498–TPS498.
   Web of Science ®Google Scholar